Brain Organoids is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Brain organoids are three-dimensional, self-organizing neural tissue structures derived from human pluripotent stem cell [2]s (hPSCs) — either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) — that recapitulate key aspects of human brain development and architecture. These miniature models of the human brain have emerged as transformative tools for studying [neurodegenerative ], enabling researchers to investigate disease mechanisms, screen therapeutic compounds, and model patient-specific pathology in ways that are impossible with traditional two-dimensional cell cultures or animal models ([Cerebral et al., 2013]](https://doi.org/10.1038).
Since the landmark development of cerebral organoids by Madeline Lancaster and Jürgen Knoblich in 2013, the field has rapidly evolved to include region-specific organoid protocols for the [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, [midbrain], cerebellum, striatum, and other brain regions (Lancaster et al., 2013. Brain organoids have proven particularly valuable for modeling [Alzheimer [5]'s disease], [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, and [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, where they reproduce hallmark pathologies including [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- plaque deposition, tau] hyperphosphorylation, [alpha.
The foundation of brain organoid technology is the reprogramming of somatic cells — typically skin fibroblasts or blood cells — into iPSCs through introduction of Yamanaka transcription factors (OCT4, SOX2, KLF4, and c-MYC). These iPSCs possess unlimited self-renewal capacity and can differentiate into any cell type, including all neural lineages. Patient-derived iPSCs carry the individual's complete genetic background, enabling personalized disease model [4]ing ([Takahashi et al., 2007]](https://doi.org/10.1016/j.cell.2007.11.019)) (Induction et al., 2007).
The original unguided approach, developed by Lancaster et al., allows iPSCs to spontaneously differentiate into diverse brain cell types without exogenous patterning factors. The process involves:
Unguided organoids contain diverse brain regions including dorsal and ventral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, choroid plexus, and retinal tissue. However, they exhibit significant organoid-to-organoid and batch-to-batch variability, which can limit reproducibility (Lancaster & Knoblich, 2014) (Individual et al., 2019.
Guided protocols use defined combinations of morphogens, growth factors, and small molecules to direct differentiation toward specific brain regions:
Cortical organoids: Dual SMAD inhibition (using SB431542 and LDN193189) drives dorsal forebrain fate. The addition of Wnt inhibition (Triple-i protocol) enhances cortical specification, producing more consistent organoids with outer radial glia and diverse neuronal subtypes (Paşca et al., 2015) (Brain et al., 2025).
Midbrain organoids: Sonic hedgehog (SHH) activation, Wnt activation (CHIR99021), and FGF8 supplementation direct differentiation toward dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, making these ideal for [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- modeling (Jo et al., 2016) (Cell et al., 2016).
Hippocampal organoids: BMP and Wnt signaling activation drives medial pallium fate, generating dentate gyrus and CA-like regions relevant to [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- memory research.
Cerebellar organoids: FGF2 and insulin signaling direct differentiation toward cerebellar progenitors, producing Purkinje [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and granule cells relevant to [Spinocerebellar Ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia--TEMP--/diseases)--FIX-- and other cerebellar degenerations.
Spinal cord organoids: Retinoic acid and SHH activation generate motor neuron progenitors, directly applicable to [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- and [spinal muscular atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy--TEMP--/diseases)--FIX-- research.
A major advance is the creation of "assembloids" — fused organoids from different brain regions that model inter-regional connectivity and circuit function. Cortical-striatal assembloids, for example, allow study of corticostriatal circuits relevant to [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--. Cortico-motor assembloids generate functional corticospinal connections relevant to [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- and motor neuron diseases. Neuroimmune assembloids incorporating [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microglia[microglia enable study of neuroimmune interactions in neurodegeneration (Birey et al., 2017.
The "Hi-Q brain organoid" protocol (2025) bypasses the traditional embryoid body stage by directly inducing iPSC differentiation into neurospheres with precisely controlled sizes using custom uncoated microplates, improving reproducibility and throughput. Air-liquid interface culture and sliced organoid methods improve oxygen and nutrient penetration, reducing necrotic cores and extending organoid viability and maturation.
Brain organoids have been instrumental in recapitulating key features of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- pathology:
Amyloid and tau] pathology: Organoids derived from iPSCs carrying familial AD mutations ([PSEN1[/genes/[psen1[/genes/[psen1[/genes/[psen1--TEMP--/genes)--FIX--, [PSEN2[/genes/[psen2[/genes/[psen2[/genes/[psen2--TEMP--/genes)--FIX--, [APP[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX-- develop extracellular [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- plaque-like deposits and intracellular tau] aggregates, faithfully recapitulating the amyloid cascade in vitro. Treatment with β- and [γ-secretase] inhibitors significantly reduced amyloid and tau] pathologies, demonstrating the model's utility for therapeutic screening (Choi et al., 2014.
APOE4 effects: Organoids from carriers of the [APOE4[/diseases/[apoe4[/diseases/[apoe4[/diseases/[apoe4--TEMP--/diseases)--FIX-- risk allele show increased [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- production, enhanced neuroinflammation, and impaired [synaptic function], providing mechanistic insight into the strongest common genetic risk factor for late-onset AD.
Neuroinflammation modeling: Organoids co-cultured with [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- reveal the role of [disease-associated [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- in AD pathogenesis, including phagocytic dysfunction, complement activation, and inflammatory cytokine production.
Midbrain organoids modeling [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- have demonstrated:
Selective [dopaminergic neuron] degeneration in organoids carrying [LRRK2[/genes/[lrrk2[/genes/[lrrk2[/genes/[lrrk2--TEMP--/genes)--FIX-- or [PINK1[/genes/[pink1[/genes/[pink1[/genes/[pink1--TEMP--/genes)--FIX-- mutations
[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--:
Motor neuron degeneration in organoids carrying [SOD1/proteins/sod1, [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX--, [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--, and FUS mutations
[Stress granule] formation and [RNA metabolism[/mechanisms/[rna-metabolism[/mechanisms/[rna-metabolism[/mechanisms/[rna-metabolism--TEMP--/mechanisms)--FIX-- defects
Non-cell-autonomous toxicity from [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- to motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
excitotoxicity and neuronal hyperexcitability
[Protein aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation--TEMP--/mechanisms)--FIX-- and impaired [proteostasis]
Striatal and cortical organoids derived from [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- patients with CAG repeat expansions in the [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- gene] exhibit:
Organoids from [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- patients with [GRN[/genes/[grn[/genes/[grn[/genes/[grn--TEMP--/genes)--FIX--, [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX--, and [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- mutations display:
Cerebral organoids have been used to model [prion diseases[/diseases/[prion-diseases[/diseases/[prion-diseases[/diseases/[prion-diseases--TEMP--/diseases)--FIX--, supporting prion propagation and neurodegeneration in vitro. This represents a significant advance, as prion diseases have been historically difficult to model in human cell systems.
Brain organoids offer several advantages for drug discovery:
Phenotypic screening: High-content imaging of organoid sections enables unbiased screening for compounds that reduce amyloid plaques, tau tangles, or [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--https://doi.org/10.1016/j.celrep.2018.05.040)).
Organoid-to-organoid and batch-to-batch variability remains a significant challenge, particularly for unguided protocols. Differences in size, cellular composition, and regional identity can impede high-throughput applications. Standardized quality control metrics — including single-cell transcriptomics benchmarking against fetal brain atlases — are being developed to address this.
Most brain organoids correspond to fetal or early postnatal brain development, whereas neurodegenerative diseases primarily affect aged adults. Current organoids lack the decades of aging processes that contribute to neurodegeneration. Strategies to accelerate organoid aging include treatment with progerin (the protein mutated in premature aging syndrome), telomere shortening, and exposure to oxidative stressors (Miller et al., 2013).
Organoids lack a functional vascular system, limiting nutrient delivery to the interior and causing necrotic cores in larger organoids. This also prevents modeling of [Blood-Brain Barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- dysfunction and [neurovascular unit[/mechanisms/[neurovascular-unit[/mechanisms/[neurovascular-unit[/mechanisms/[neurovascular-unit--TEMP--/mechanisms)--FIX-- pathology in neurodegeneration. Efforts to vascularize organoids include co-culture with endothelial cells, microfluidic perfusion systems, and transplantation into mouse brains.
Standard brain organoid protocols may underrepresent certain cell types critical to neurodegeneration, including [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--, high cost, and manual handling required limit throughput for large-scale drug screening. Automation, miniaturization, and organ-on-chip integration are active areas of development.
Combining single-cell RNA sequencing, spatial transcriptomics, proteomics, and metabolomics on brain organoids provides unprecedented resolution into disease mechanisms and drug responses.
Establishment of standardized organoid biobanks from genetically characterized patient cohorts will enable large-scale, reproducible studies and cross-laboratory comparisons.
Integration of brain organoids with microfluidic chips enables controlled perfusion, multi-organ interactions (e.g., gut-brain organoid systems relevant to the [Gut-Brain Axis), and real-time monitoring of neuronal activity.
Patient-derived organoid-based drug sensitivity testing may guide personalized treatment decisions, particularly for genetically defined forms of neurodegeneration where multiple therapeutic options exist.
As organoid complexity and size increase, ethical questions arise regarding consciousness, sentience, and the moral status of brain organoids. The field is developing frameworks for responsible organoid research, particularly as organoids show increasing neural circuit activity and oscillatory patterns.
The study of Brain Organoids has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.